CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
about
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaClinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkersThe use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and researchThe Global Alzheimer's Association Interactive NetworkSharing data in the global alzheimer's association interactive networkTracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersDiagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's DiseaseRelationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNIPhosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementiaTDP-43 suppresses tau expression via promoting its mRNA instability.Neurodegenerative disease: MRI biomarkers - a precision medicine tool in neurology?The power of neuroimaging biomarkers for screening frontotemporal dementia.The future of blood-based biomarkers for Alzheimer's disease.Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometryThe influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluationsFrontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease familyThe transitional association between β-amyloid pathology and regional brain atrophyMemory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient AutopsiesApplied multimodal diagnostics in a case of presenile dementia.Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's DiseaseIdentifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study.Premotor biomarkers for Parkinson's disease - a promising direction of research.Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.Multilevel Deficiency of White Matter Connectivity Networks in Alzheimer's Disease: A Diffusion MRI Study with DTI and HARDI ModelsPathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.Can MRI screen for CSF biomarkers in neurodegenerative disease?White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairmentLate-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratiosPlasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarkerWhite matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration
P2860
Q26864063-4275EC15-0C19-4A90-AA42-77FFEC746C50Q27008249-6D939933-2FA4-4DCC-A8CF-2CE633DE47DCQ28088291-6DC8E22F-0587-40F7-9E44-AE8C98F92545Q28601466-59133439-DC78-43A0-AE51-E80F6EA1077DQ28607247-D730611D-9DC2-4812-927A-1ECA157D2316Q29620245-C59EAA40-A006-433D-9249-4EA5C0788509Q30659251-7F91D03A-9981-4F5B-87EA-C7BC935192A9Q31110973-708302B4-C1F2-4343-8583-CA90A8ED632AQ33554802-6980F096-725D-4055-ACF3-3D5722A62580Q33559175-F84F76B4-3020-427F-8A13-694988C5B822Q33666297-C328581B-6694-4D69-A653-6835AAA37FA2Q33727909-4DE59DAE-05D6-4387-82AF-7CB4C9DC9E83Q33740999-ACDBFECA-63CC-46D2-8001-8FB5B6A222CAQ33907524-2817790E-A47C-4E18-9D9C-60A50121DDB9Q33934175-435AEAC2-6A47-4672-8419-5CD870EE6094Q34026317-11DF3FA6-4CB3-40E9-81FD-1D60E61E0784Q34079305-8186C52E-2A7F-4A7E-9F9C-71499136EFEDQ34157882-1280F0F9-81A3-4C18-9568-CAD3E83B58E0Q34873817-3B60721D-6706-4174-A116-68AFB81D1058Q35204586-4420B7C3-9737-45EF-B8D5-67E706C41A32Q35686163-08F9AA43-8B51-424E-9413-29FF1366882AQ35706871-D2E59419-B135-4254-98F1-982DAB9403F7Q35889053-44455FC3-83A6-4A9D-BA42-404ACDD43C94Q36030708-1892DFC5-8E3E-468E-88A9-1A35E3CA4F04Q36099506-B41998D9-9D96-4DDF-BF0D-152DBDE3793DQ36157458-FF3822ED-E95E-4238-AD83-123EF488314CQ36271739-1BC44043-B8B7-472B-B079-872A946CBB9BQ36276506-7704A4EC-CA09-4455-9AC3-688EAC6CC363Q36322982-0BB17D97-4C7E-4832-825C-36D41723D8E8Q36353787-7F5DCBF2-3574-4650-B858-12DA7E5CCEA5Q36444517-A31B96C3-F604-4017-9011-AB06812FFB6CQ36527483-377DA35B-6A8B-48EB-BA77-4FA47E9BCD30Q36533528-D54D3438-5EEE-4534-B82D-56BF1D4B010DQ36581696-52ADAB39-9B65-4F4B-98FC-F1C95C5FB1E5Q36626657-6130A1BB-8C43-48C5-90F9-541659CDD5F3Q36659380-3310AE34-721B-4BA1-BF3B-8010AF14CF5EQ36874831-DEF190EC-4AAF-4F67-AA92-07E108B2494EQ36930623-3BC35195-E8C5-4BB1-9237-C8D2769D0AAFQ36998414-45096222-9D29-4610-9DCF-36BDFE815407Q37079742-52E06456-EC6D-4752-9407-40E752104B8F
P2860
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@ast
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@en
type
label
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@ast
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@en
prefLabel
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@ast
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@en
P2093
P2860
P50
P1476
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
@en
P2093
Johannes Brettschneider
Jon B Toledo
Leslie M Shaw
Sharon X Xie
Virginia M-Y Lee
William T Hu
P2860
P2888
P356
10.1007/S00401-012-0983-7
P577
2012-04-22T00:00:00Z